Artiva Biotherapeutics ARTV
NASDAQ ARTV
$6.20 -0.29 (-4.47%)
At close: Oct 22, 2026 · 4:00 PM EDT

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025)

Updated

Artiva Biotherapeutics' Capital Leases was $11,000 in Q1 2025, down 75.0% from the prior quarter.

Analysis

Artiva Biotherapeutics (ARTV) Capital Leases (2024 - 2025) Analysis & Trends

At the end of FY2024, Capital Leases at Artiva Biotherapeutics came in at $44,000.

  • Per Business Quant data, ARTV's Capital Leases in the three quarters before Q1 2025 was $44,000 (Q4 2024), $75,000 (Q3 2024) and $106,000 (Q2 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Artiva Biotherapeutics 244.36 Mn -105.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 11,000.00
Dec 31, 2024 44,000.00
Sep 30, 2024 75,000.00
Jun 30, 2024 106,000.00
API Access

Artiva Biotherapeutics Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=ARTV&period=max&api_key=YOUR_API_KEY